Enterprise Value
481.7M
Cash
68.78M
Avg Qtr Burn
-25.55M
Short % of Float
2.86%
Insider Ownership
10.05%
Institutional Own.
61.46%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Botaretigene sparoparvovec (AAV-RPGR) Details Genetic disorder, Eye disease , X-linked retinitis pigmentosa | Phase 3 Data readout | |
AAV-RPE65 test Details Eye disease , Retinal dystrophy | Phase 3 Initiation | |
AAV-CNGA3 Details Achromatopsia | Phase 2b Initiation | |
AAV-CNGB3 Details Achromatopsia, Genetic disorder, Skin disease/disorder, Autosomal recessive congenital ichthyosis | Phase 1/2 Update | |
AAV-hAQP1 Details Salivary gland | Phase 1 Data readout | |
AAV-GAD Details Parkinson's disease | Phase 1 Update |